Search
Evening primrose oil
go.drugbank.com/drugs/DB11358ApprovedNutraceuticalEvening primrose oil comes from the extraction from Oenothera biennis seeds and it is commonly used as an alternative source for omega-6 essential fatty acids. In its composition it presents some fatty acids such as DB00132 and DB13854. ...
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 Enzyme InhibitorsCarbomycin
go.drugbank.com/drugs/DB11383ExperimentalVet approvedCarbomycin, also called magnamycin, is crystalline macrolide antibiotic. This antibacterial is obtained from Streptomyces halstedii and it presents a large inhibitory effect against Gram-positive bacteria and some Mycoplasma strains. The...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsEprinomectin
go.drugbank.com/drugs/DB11405ExperimentalVet approvedCategories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsSalinomycin
go.drugbank.com/drugs/DB11544ExperimentalVet approvedCategories: P-glycoprotein inhibitorsLesinurad
go.drugbank.com/drugs/DB11560ApprovedWithdrawnLesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptak...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersInsulin tregopil
go.drugbank.com/drugs/DB11568InvestigationalCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersRupatadine
go.drugbank.com/drugs/DB11614ApprovedInvestigationalRupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesTucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tuca...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsBryostatin 1
go.drugbank.com/drugs/DB11752InvestigationalBryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsAZD-1305
go.drugbank.com/drugs/DB11766InvestigationalAZD1305 has been used in trials studying the treatment and basic science of Atrial Flutter, Atrial Fibrillation, and Left Ventricle Function.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates